PTM GS-5718 clinical trials

A Randomized, Blinded, Placebo Controlled, Phase 2a Proof-of-Concept Study to Evaluate Efficacy, Safety, and Tolerability of GS-5718 in Participants with Cutaneous Lupus Erythematosus (CLE)

This study is testing a new tablet, GS-5718, for people with a skin condition called Cutaneous Lupus Erythematosus (CLE). We want to see if the drug helps reduce skin problems caused by CLE and if it's safe to use.